Demographic and clinical profiles of type 2 diabetes mellitus patients initiating sitagliptin in the real-world setting

AbstractObjective: Dipeptidyl peptidase-4 (DPP-4) inhibitors have been used for the management of type 2 diabetes (T2D) for over a decade; however, there is a limited understanding of the evolution of their use in the real-world setting over this time period. This study evaluated the demographics and clinical characteristics of patients initiating sitagliptin over a 10 year period in the United States.Research design and methods: Quintiles electronic medical records database was used to identify adults with a new prescription of sitagliptin over two 5 year time periods: 2006–2010 (n = 57,604), and 2011–2015 (n = 147,326). In addition, we also evaluated how the most recent (year 2015) profile of sitagliptin initiators (n = 29,295) compares to the treated T2D patients (N = 474,877) in 2015.Main outcome measures: No outcomes were assessed. Descriptive statistics were used to summarize baseline patient characteristics.Results: The overall demographics and clinical characteristics of patients initiating sitagl...